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Introduction
Local anesthesia is the most widely used method for con-
trolling pain during the intra-operative period (Whiteside 
& Wildsmith, 2001). Although it is an effective method, 
the conventional local anesthetic agents clinically used 
are characterized by short duration of analgesia and both 
systemic and local toxicity (Cox et al., 2003). For this rea-
son, care should be taken regarding the right choice of 
local anesthetic with a preference for one that is most 
effective and has the lowest concentration of anesthetic 
salt and vasoconstrictor.
Liposomes have been extensively described in the 
literature for their use as drug carriers (Torchilin, 2005; 
Samad et al., 2007). The distinct advantage of liposomes 
is their structural versatility combined with their ability 
to encapsulate different compounds, including local 
anesthetics (Felnerova et al., 2004).
The advantages of liposome encapsulated local 
anesthetics are slow drug release, prolonged anesthetic 
effect, and reduced toxicity for both the cardiovascular 
and central nervous system (Gesztes & Mezei, 1988; 
Langerman et al., 1992; Boogaerts et al., 1993a; b; 
Mowat et al., 1996; Bucalo et al., 1998; de Araujo et al., 
2003). The vasoconstrictor is usually absent in liposome 
encapsulated anesthetics formulations. The pharma-
cological effectiveness of many liposomal-anesthetic 
preparations has been demonstrated by studies using 
animals (Mashimo et al., 1992; Boogaerts et al., 1993a; 
b; Malinovsky et al., 1997; Grant & Bansinath, 2001; 
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Abstract
The pharmacokinetics and the local toxicity of commercial and liposome-encapsulated mepivacaine for-
mulations injected intra-orally in rats were studied. Animals were divided in groups (n = 4–6) and treated 
with 0.1 mL of the formulations: 2% mepivacaine with 1:100,000 epinephrine (MVC2%EPI), 3% mepivacaine 
(MVC3%), and 2% liposome-encapsulated mepivacaine (MVCLUV). The results showed that the 2% liposome-
encapsulated mepivacaine reduced Cmax, prolonged AUC0–∞ and t1/2 compared with 3% plain and 2% 
 vasoconstritor-associated mepivacaine, after intraoral injection. In addition, it was also observed that lipo-
somal mepivacaine might protect the tissue against local inflammation evoked by plain or vasoconstrictors-
 associated mepivacaine, giving supporting evidence for its safety and possible clinical use in dentistry.
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Yu et al., 2002) and human beings (Lafont et al., 1994; 
1996; Boogaerts et al., 1994; Grant et al., 2004).
Mepivacaine was the second amide to be introduced 
as a local anesthetic. It has a fast onset; similar to that of 
lidocaine, and it is a popular choice for a wide range of 
regional anesthetic procedures due to its safety (McLure 
& Rubin, 2005). Liposome encapsulated mepivacaine 
increased the analgesic effect in relation to ampli-
tude and anesthetic duration (de Araujo et al., 2004). 
Moreover, encapsulation of mepivacaine in liposomes 
greatly enhanced the infraorbital nerve block in rats when 
compared with the plain solution of this local anesthetic 
(Cereda et al., 2006).
In developing a new pharmaceutical form, such as 
liposomal mepivacaine, the International Conference 
on Harmonization requires pharmacokinetic and local 
toxicity assessments in animals. Thus, the aims of this 
study were to determine plasma concentrations and to 
evaluate the tissue reaction induced by liposomal mepi-
vacaine compared with commercial formulations after 
intra-oral injections in rats, looking forward to its clinical 
use in dentistry.
Materials and methods
2% Mepivacaine with 1:100,000 epinephrine-MVC
2%EPI
 
(Mepiadre®-DFL Indústria e Comércio S.A., Rio de 
Janeiro, RJ, Brazil) and plain 3% mepivacaine-MVC
3%
 
(MepiSV®-DFL Ind. Com. S.A., Rio de Janeiro, RJ, Brazil) 
were purchased in local commerce. Liposomal suspen-
sion of 2% mepivacaine-MVC
LUV
 was prepared with 
mepivacaine hydrochloride salt supplied by Cristália 
Ind. Quim. Farm. Ltda (Itapira, SP, Brazil). EDTA titriplex 
was purchased from Merck KGaA and sodium thiopental 
solution (Thiopentax®) from Cristália Ind. Quim. Farm. 
Ltda. Alpha-chloralose, urethane, alpha-tocopherol 
acetate, egg phosphatidylcholine, and cholesterol 
were obtained from Sigma Chem. Co (St Louis, MO). 
Acetonitrile used was of HPLC grade. Other reagents 
were of analytical grade.
Liposomal formulations: Preparation and serilization
A dry lipid film, containing egg phosphatidylcholine, 
cholesterol, and α-tocopherol at a 4:3:0.07 molar ratio 
was prepared by solvent evaporation under nitrogen 
flow (Boogaerts et al., 1993a; b; Fraceto et al., 2002). 
Multilamellar liposomes were obtained by adding 
20 mM HEPES buffer, pH 7.4 (containing 154 mM NaCl) 
to the dry lipid film and vortexing the mixture during 
5 min. Unilamellar-liposome vesicles (0.4 μm) were 
prepared by extrusion (12 cycles through 400 nm poly-
carbonate membrane, at 25°C) of the multilamellar vesi-
cles. The total lipid concentration in the LUV was 5 mM 
(Cereda et al., 2008). Mepivacaine was added directly to 
the liposomes after extrusion, up to a concentration of 2% 
(corresponding to 70.7 mM of mepivacaine). Liposome 
formulations were incubated for 12 h and stored at 4°C 
until further use.
The preparations were sterilized by autoclaving (121°C, 
1 atm, and 15 min). Afterward, the sterility was evaluated 
by microbiological test with Brain-Heart Infusion (BHI) 
and apyrogenicity was assessed by Endosafe® Limulus 
Amoebocyte Lysate Test.
Animals
Male Wistar rats, 250–350 g, were obtained from CEMIB–
UNICAMP (Centro de Bioterismo, State University of 
Campinas, UNICAMP, SP, Brazil) and they received water 
and food ad libitum. Animals were randomly divided in 
groups (n = 4–6/group) and protocols were approved by 
the Institutional Committee for Ethics in Animal Research 
of the State University of Campinas (protocols #1067-1 
and 871-1), which follows the recommendations of the 
Guide for the Care and Use of Laboratory Animals.
Pharmacokinetic study: Experimental design
The animals were divided into three groups and they 
received intra-orally 0.1 mL of one of the following treat-
ments: Group 1, 3% plain mepivacaine (MVC
3%
); Group 2, 
2% mepivacaine with 1:100.000 epinephrine (MVC
2%EPI
); 
and Group 3, liposomal 2% mepivacaine (MVC
LUV
). The 
selection of local anesthetic concentration in the lipo-
somal formulation was determined by the efficacy of 
2% liposomal mepivacaine shown in previous studies 
(de Araujo et al., 2004; Cereda et al., 2006).
General anesthesia was performed with α-chloralose 
(50 mg/kg) and urethane (1 g/kg) before the injections. A 
prior pilot assay (data not shown) showed no influence of 
general anesthesia on the mepivacaine pharmacokinet-
ics. An intravascular catheter was inserted in the femoral 
vein and 0.2 mL blood samples were collected right before 
the anesthetic injection (0 min) and at 15, 30, 45, 60, 120, 
180, 240, 300, 360, and 420 min after the anesthetic injec-
tion. These intervals were defined to obtain 10 samples 
between the baseline (0 min) and ∼ 4-times the t
1/2
 (half-
life) of mepivacaine (1.5 h) (Covino & Vassalo, 1976). This 
geometric progression scheme is commonly used and 
supplies information about drug disposition (Bourne, 
1995). Samples were transferred into heparinized tubes 
and the separated plasma was stored at −70°C.
LC–MS/MS assay: Apparatus and chromatographic 
conditions
A Waters® HPLC system (2795) coupled to a Micromass 
Quattro Premier XE triple stage quadrupole mass 
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spectrometer, equipped with API electrospray source 
was used. Separations were performed using a C18 
polaris 5 µm, 50 mm × 2 mm i.d. The mobile phase was 
80% acetonitrile and 20% water (with 0.1% formic acid). 
The total run time was 3.0 min. The mass spectrometer 
was run in the positive mode (ES+) and set for multiple 
reaction monitoring (MRM). The full-scan single-mass 
spectrum and the daughter ion-mass spectrum for 
mepivacaine and Venlafaxine (internal standard; IS) 
were (m/z) 247.5 > 150.5 and 278.1 > 215.31, respec-
tively. The data were integrated using the MassLynx 4.1 
(Waters®) software. The WinNonlin 5.2 computer pro-
gram (Pharsight, USA) was used to calculate the phar-
macokinetic parameters. Quality control samples (QC) 
prepared by mixing drug-free plasma with appropriate 
volumes of working solutions were used to validate the 
method.
Plasma sample preparation
The extraction procedure was performed by transferring 
80 µL of plasma to test tubes, followed by the addition of 
25 µL of IS working solution. The samples were vortexed 
for 1 min and 50 µL of 1 M NaOH were added followed 
by 1 min vortexing; 1000 µL of hexane/ethyl acetate 
(1:1, v/v) was added to each tube. After centrifrugation 
(5 min), 800 µL of the organic phase were removed to 
clean tubes and the solvent was evaporated under nitro-
gen flow (N
2
) at 37°C. Each sample was then diluted in 
100 μL of mobile phase, agitated for 2 min, and trans-
ferred to LC-MS/MS system vials, for further injection 
(5 μL).
Local toxicity study: Surgical procedure
Slightly general anesthesia was induced by an intra-
peritoneal injection of sodium thiopental solution 
(40 mg/ kg), before the administration of the local 
anesthetic formulations. The animals were divided into 
four groups and received 0.1 mL of one of the following 
formulations: MVC
2%EPI






liposomal 2% mepivacaine; and LUV-mepivacaine-free 
liposome.
The animals received one of the formulations in the 
oral mucosa of the upper right first molar, as previously 
described by Cereda et al. (2008). The same amount of 
saline solution (NaCl 0.9%) was administered in the left 
side as control. Animals were sacrificed under anesthesia 
(urethane 1 g/kg and alpha-chloralose 50 mg/kg) 6 h, 24 h, 
and 4 days after treatment, and the maxilla bones along 
with soft tissues were removed. Before the administration 
of the formulations, their pH values were measured with 
a pHmeter ORION®, model 290A, with a microelectrode 
LAZAR BNC.
Histological analysis
The samples were fixed with Bowin solution during 24 h 
and with 10% formalin solution for 48 h, and decalcified 
with EDTA titriplex (Merck KGaA). Five cross-sections (6 
µm thick, 40 μm deep) were obtained from each animal 
sample. The cross-sections were stained with hema-
toxylin and eosin. The cross-sections were submitted to 
qualitative analysis in order to evaluate the intensity of 
the leucocitary infiltration and/or any area of necrosis. 
The cross-sections were photographed by a photomicro-
scope (Zeiss-AXIOSKOP2-PLUS). The analyzed region 
was the site of the injection and it enclosed the connec-
tive tissue in the most internal portion of the anterior 
maxillary fornix. A preliminary pilot study conducted 
using methods developed in previous studies (Scheib 
& Garner, 2004; Shipper et al., 2005) allowed the use of 
a qualitative score of the local tissue inflammation. The 
score was defined based on the following descriptions: 
(1) no infiltrate; (2) minimal infiltrate; (3) mild infiltrate; 
(4) severe infiltrate; and (5) severe infiltrate with necro-
sis areas (Cereda et al., 2008).
The images were codified and two individuals blinded 
to treatment conditions evaluated the images according 
to the qualitative score previously described. The rep-
lication of the classification method between the two 
examiners was calculated by the intra-class correlation 
test for continuous data.
Statistical analysis
The plasmatic mepivacaine concentrations were ana-
lyzed by one-way ANOVA and the Tukey-Kramer test 
(post-hoc) considering each period of time separately 











) were analyzed using the Kruskal-
Wallis test and Student-Newman-Keuls as post hoc test 
(α = 0.05). The results obtained in each time interval (6 h, 
24 h, and 4 days) were compared considering each group 
and considering the control side. Data were analyzed with 
the Kruskal-Wallis test considering each group (inter-
group analysis). The tissue reaction was also analyzed 
by Wilcoxon paired test considering treated and control 




The calibration graph for mepivacaine was generated 
with increasing amounts of the drug standards. A good 
response over the range of 1.0–1000.0 ng/mL was shown 
and presented linearity with high correlation coeffi-
cient (r = 0.99972). The precision and accuracy of the 
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method were assessed by determination of seven con-
centrations in three independent series of spiked serum 
samples. The accuracy and precision were calculated to 
be from 92.45–105.5% and from 0.4–9.8%, respectively. 
The 95% confidence intervals were 92.97–106.83% 
considering accuracy and 6.84–7.03% for precision. In 
addition, the limit of quantification (LOQ) was set as 
the lowest measurable concentration with acceptable 
accuracy and precision. The LOQ for mepivacaine was 
set to 1 ng/mL.
Figure 1 shows the graph of mean plasma concen-







. Table 1 reports the median (lower and upper 
quartiles) values of the pharmacokinetic parameters 
obtained after intra-oral injections of the tested formu-
lations. MVC
3%
 induced higher plasma concentrations 
than MVC
LUV
 after intra-oral injection for periods of 
time up to 240 min (p < 0.05). After this period, no sta-
tistically significant difference was observed between 
the two formulations (p > 0.05). MVC
3%
 also induced 
higher plasma concentrations than MVC
2%EPI
 at 15, 120, 
180, and 240 min (p < 0.05). Statistical differences were 





 for all periods of time (p > 0.05) 
(Figure 1).







 values when compared 
to MVC
3%
 (2.2- and 10-times, respectively) and MVC
2% EPI
 
(12- and 15-times, respectively), as observed in Table 1 
(p < 0.01). However, MVC
3%
 showed statistically different 
(p < 0.001) C
max
 values compared to MVC
LUV.
In the present study, mepivacaine analysis was dis-
continued at 420 min since the blood collection period 
could not be prolonged due to the volume of blood col-
lected at each time point (0.4 mL). However, the analysis 
demonstrated that the plasma concentrations obtained 
with aqueous mepivacaine solution were higher than 
those obtained with the liposome formulation, similar 
to the results obtained by Boogaerts et al. (1993b).
Determining drug concentration in biological fluids 
provides the fundamental information needed for the 
development of new drug forms (Altun et al., 2004), such 
as liposome preparations of local anesthetics. Moreover, 
pharmacokinetic determinations are fundamental in 
clinical practice (Adams et al., 1989). Although there are 
several methods for quantifying drug components, liquid 
chromatography with mass spectrometry (LC-MS/ MS) 
is considered the technique of choice for biological fluid 
analysis (Cobb & Andersson, 2005). The LC-MS/MS 
system used in this study is one of the most utilized 
analytical tools for determining pharmacokinetic 
parameters of a drug with high precision and reliability 
(Korfmacher, 2005).
There are no previous reports that compare the 
absorption of local anesthetics, free as well as liposome-
encapsulated, after an intra-oral injection. Several stud-
ies assess the absorption of liposome-ncapsulated local 
anesthetics such as: epidural in dogs (Mashimo et al., 
1992), intra-articular in rabbits (Hou & Yu, 1997), sub-
cutaneous in rats (Yu et al., 2002), and during axillary 
block in rabbits (Boogaerts et al., 1993b). Despite these 
methodological differences, the results obtained in the 
present study are compatible with those obtained by 
those authors.
Hou and Yu (1997) evaluated the pharmacokinetics 
of aqueous lidocaine and liposome lidocaine after an 
intra-articular injection in rabbit knees. These authors 
observed that the liposome drug was absorbed to a lesser 
extent than non-vasoconstrictor-containing lidocaine, 
which was similar to the findings of this study. This may 
have occurred due to the slow release of the anesthesia 
by the liposomes.
Boogaerts et al. (1993b) compared plasma concen-
trations of bupivacaine after administration of free 
bupivacaine and a complex with multilamellar lipo-
somes during axillary block in rabbits. Those animals 
given liposome bupivacaine had lower plasma levels 
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demonstrating that the slow release of the anesthetic was 
responsible for its prolonged action.
Mashimo et al. (1992) showed the pharmacokinetics 
of free and liposome encapsulated lidocaine in dogs 
after epidural administration. The areas under the 
curve (AUC) and T
max
 were greater in animals given 
liposome encapsulated lidocaine, contrary to the 
observations in this study that revealed smaller param-
eters for liposome formulations compared with free 
formulations of the local anesthetic. These differences 
may be explained by the type of local anesthetic agent 
used in this study as well as the distinct concentrations 
and vasoconstrictors, since the commercial formula-
tions with mepivacaine used here were similar to those 
used in clinical dentistry. Moreover, the different route 
of administration may have contributed towards these 
differences.
Yu et al. (2002) studied the pharmacokinetics of free 
and liposome bupivacaine after injecting these formu-
lations in rat tails. In this study, the blood was collected 
from the animals hourly for 480 min. These authors 
described that C
max
 value was 5-times greater for the 
non-encapsulated anesthetic. In the present study, the 
C
max
 obtained after injecting MVC
3%
 was 7-fold greater 
than that obtained after injecting MVC
LUV
. Likewise, 
Yu et al. (2002) obtained smaller AUC values for lipo-
somal formulations. Even if statistical differences were 





 was less than half that obtained 
after injecting MVC
3%
. This difference is probably not 
only due to encapsulation of the anesthetic but also due 
to the different mepivacaine concentrations in these 
formulations. The results presented in the present 
study are similar to those observed by Yu et al. (2002), 
showing the liposomal anesthetic preparation main-
tained a constant plasmatic level when compared with 
a non-encapsulated common anesthetic without a 
vasoconstrictor. In this manner, the results obtained by 
the present study as well as the documented anesthetic 
efficacy (de Araujo et al., 2004; Cereda et al., 2006) indi-
cate a promising future for liposomal formulations of 
mepivacaine.














0.27 (0.21–0.33) 150 (120–195) 92.7 (72.3–111.9) 776.1 (424.1–1221.5)a,c** 1465.2 (911.6–2822.4)a,c**
MVC
3% 1.90 (1.24–2.42)
a** 120 (120–120) 241.4 (221.0–248.9)a,b** 349.3 (257.0–454.7) 145.2 (49.0–315.9)
MVC
2% EPI
0.40 (0.33–0.48) 90 (60–195) 66.7 (61.2–115.9) 60.1 (46.5–65.2) 94.9 (89.7–226.5)
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bar: 20 µm.
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Local toxicity evaluation
Figure 2 shows transverse sections of the maxilla bones 
and their surroundings soft tissues 6 h, 24 h, and 4 days 






, or empty 
liposomal vesicles (LUV). The pH values of each formu-
lation were verified as follows: commercial mepivacaine 
formulation without vasoconstrictor, 0.9% NaCl, and 
mepivacaine with vasoconstrictor formulation showed 
similar pH values of 5.5, 5.8, and 3.8, respectively. The 
liposomal mepivacaine (7.1) and the mepivacaine free 
liposome (liposome vesicles) (7.3) had a pH value on 
the physiologic range. As quality control assay of the 
histological examination, the intra-class correlation test 
showed an index of 0.96 (p < 0.0001), indicating agree-
ment between both examiners.
Figure 3 shows the median scores for intensity of the 
inflammatory reaction after the injection of different 
mepivacaine formulations (inter-group analysis). At 6 h 
after injection, MVC
2%EPI
 had higher inflammatory scores 
compared to MVC
LUV
 (p = 0.0043) and LUV (p = 0.0012). 
However, MVC
3%
 did not show statistically significant 
differences from MVC
2%EPI
 (p > 0.05). In addition, no 
differences were observed between MVC
LUV
, LUV, and 
MVC
3%
 (p > 0.05). After 24 h, the results followed the 
same profile observed at 6 h. However, after 4 days the 





 (p = 0.0096).
The right (treated) and the left (control) sides of the 
maxilla of each animal were compared (intra-group analy-
sis). Considering the intra-group analysis after 6 and 24 h of 





showed higher inflammatory reaction scores (p < 0.05) 
when compared to their controls. Non-significant differ-
ences were observed after the administration of MVC
LUV
 
and LUV when compared to their controls (p > 0.05). 
Four days after the treatment, the group treated with 
MVC
2%EPI
 still had higher scores when compared with the 
control side (p < 0.05). Non-significant differences were 





LUV when compared to their controls (p > 0.05). Table 2 
demonstrates the median values of the scores obtained 
after the treatments and their controls.
The tissue reaction induced by local anesthetic solu-
tions or by liposomal formulations of local anesthetics 




Test side Control side (saline solution)
6 h 24 h 4 days 6 h 24 h 4 days
MVC
2% EPI 4.8 (4.2–5.0)
a**,b** 4.0 (3.8–4.0)a**,b** 2.5 (2.0–3.0)c** 2.5(2.0–3.0)d*** 2.0 (2.0–2.4)d*** 1.7 (1.0–2.0)d***
MVC
3%
3.3 (3.0–4.2) 3.0 (2.6–3.2) 2.0 (1.8–2.0) 2.1 (2.0–2.6)e** 2.0 (2.0–2.4)e** 1.6 (1.4–2.0)
MVC
LUV
2.5 (2.0–3.2) 2.0 (2.0–2.6) 1.3 (1.0–2.4) 2.5 (2.0–3.0) 2.1 (2.0–2.8) 1.6 (1.0–2.0)
LUV 2.3 (2.0–2.8) 2.1 (2.0–2.8) 1.9 (1.6–2.4) 2.4 (2.0–3.4) 2.0 (2.0–2.8) 1.9 (1.4–2.2)
Statistical analysis: p < 0.001 (***), p < 0.01 (**), p < 0.05 (*), p > 0.05 (non-significant).










. Intra-groups (Wilcoxon paired test): d MVC
2%EPI
 vs 
control (saline); e MVC
3%















Figure 3. Scores of the intensity of the inflammatory reaction (Central line: median; Box: lower and upper quartiles; Whisker: maximum and 
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was previously evaluated (Malinovsky et al., 1997; 
Ribeiro et al., 2003). However, the present study evalu-
ated the oral tissue reaction to mepivacaine liposomal 
anesthetic formulation. This local toxicity evaluation 
is necessary for future use in human subjects. Those 
studies were performed using polyethylene tubes 
containing absorbent-paper cones soaked in different 
anesthetic solutions (lidocaine, mepivacaine, artic-
aine, and bupivacaine), implanted subcutaneously 
in the backs of rats. According to this previous study, 
this method could promote a more prolonged contact 
between local anesthetics and tissues and easily would 
allow the localization of the implanted area (Ribeiro 
et al., 2003). In the present study, the site of the injec-
tion was the oral mucosa close to the upper first molar. 
This area was used to better simulate the inflammatory 
reaction in oral sites and it also allowed the use of the 
upper first molar to locate the injection area. Besides 
the differences in methodological approaches, both 
of the studies showed that local anesthetics induce 
inflammatory reactions.
A 0.9% NaCl solution induced a more intense inflam-
matory reaction when compared with plain 2% lidocaine 
solution, probably due to the vasodilator effect of lido-
caine, which could cause a rapid absorption and elimina-
tion of the anesthetic from the site of the injection (Ribeiro 
et al., 2003). In our study the plain  mepivacaine solution 
evoked more intense inflammatory reactions compared 
to the 0.9% NaCl solution at 6 and 24 h periods after treat-
ment. The low vasodilator effect of mepivacaine allows 
longer residence in the site of injection and increases the 
possibility of tissue irritation, and could be responsible 
for the more intense inflammatory reaction.
Along with the local anesthetic properties, another 
important factor to consider regarding the inflamma-
tory response was the presence of vasoconstrictors. In 
fact, the pH of local anesthetics with sympathomimetic 
amines (epinephrine, norepinephrine, levonorde-
phrin, and phenylephrine) is usually in the pH range 
of 3.5–5.5 (USP XXII). This is necessary to avoid the 
oxidation of the sympathomimetic amines (Murakami 
et al., 1994). In this study, the pH of the 2% mepivacaine 
with 1:100,000 epinephrine solution was 3.8. This low 
pH could have contributed for the high levels of inflam-
matory reaction induced by this solution at 6 and 24 h 
after administration. Previous studies reported adverse 
effects associated with the use of acidic solutions. These 
solutions could cause discomfort and pain during or 
after the injection, and retard the onset of anesthesia 
(Oikarinen et al., 1975; Murakami et al., 1994; Meechan 
& Day, 2002; Wahl et al., 2002).
Previous studies showed that a single intrathecal 
injection of plain epinephrine (up to 0.5 mg) is not 
associated with histological injury in rabbits (Oka et al., 
2001) or rats (Bahar et al., 1984; Hashimoto et al., 2001). 
However, epinephrine worsens histological spinal cord 
injury when added to 5% lidocaine in rats (Hashimoto 
et al., 2001) or 1–2% tetracaine in rabbits (Oka et al., 
2001). Thus, it seems that the addition of epinephrine to 
a potential irritating substance (local anesthetic) wors-
ens the tissue reaction. In our study the injection of 1 µg 
of epinephrine with 2% mepivacaine produced the most 
intense inflammatory reaction when compared to the 
saline control and to the other formulations. The low pH 
and the prolonged tissue exposure to the local anesthetic 
caused by the vasoconstrictor action of epinephrine 
could explain the more intense inflammatory reaction of 
MVC
2%EPI
. In addition, the use of vasoconstrictors evokes 
ischemia, hypoxia, and important cell injury (Kumar 
et al., 2007). This feature could explain the increased 
toxic effects observed after the injection of the MVC
2%EPI
 
formulation. The liposomal formulations, with a pH in 
the physiologic range, with or without mepivacaine, 
did not promote an inflammatory reaction higher than 
the one evoked by the injection of 0.9 % NaCl solution. 
Histopathology characteristics of the spinal cord of rab-
bits were evaluated after an intra-cisternal injection 
of plain and liposomal bupivacaine, both at 0.5%, and 
bupivacaine free liposomes (Malinovsky et al., 1997). 
These authors observed that the injection of liposomal 
bupivacaine did not produce histopathological changes 
in the spinal cord different from those evoked by the 
plain solution. Despite methodological differences, 
our study showed similar results, since the injection of 
liposomal mepivacaine did not produce an inflamma-
tory reaction more intense than the injection of plain 
mepivacaine (MVC
3%
), mepivacaine free-liposomes, and 
0.9 % NaCl solution.
Conclusion
Results from our study indicate that 2% liposome-







 compared with 3% plain and 2% 
vasoconstritor-associated mepivacaine, after intra-oral 
injection. In addition, liposomal mepivacaine might 
protect the tissue against local inflammation evoked by 
plain or vasoconstrictors-associated mepivacaine, sup-
porting its safety and possible clinical use in dentistry. 
This formulation could be considered an alternative 
to the use of vasoconstrictor-containing local anes-
thetic formulations when the vasoactive compound is 
contraindicated.
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